Conversely, in primary OA, MetS upregulates critical factors, including ACAN, PANX3, CLU, and VAT1L, enhancing cartilage catabolism, inflammation, and extracellular matrix stiffness, mediated by the accumulation of advanced glycation end products (AGEs). The gene discussed is PANX3; the disease is metabolic syndrome.